Lisata Therapeutics, Inc. (LSTA)
| Market Cap | 28.74M |
| Revenue (ttm) | 170,000 |
| Net Income (ttm) | -16.59M |
| Shares Out | 9.03M |
| EPS (ttm) | -1.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,419 |
| Open | 3.140 |
| Previous Close | 3.120 |
| Day's Range | 3.120 - 3.210 |
| 52-Week Range | 1.810 - 5.070 |
| Beta | 1.11 |
| Analysts | Buy |
| Price Target | 15.00 (+371.4%) |
| Earnings Date | May 11, 2026 |
About LSTA
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headq... [Read more]
Financial Performance
In 2025, Lisata Therapeutics's revenue was $170,000, a decrease of -83.00% compared to the previous year's $1.00 million. Losses were -$16.59 million, -17.01% less than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for LSTA stock is "Buy." The 12-month stock price target is $15.0, which is an increase of 371.40% from the latest price.
News
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
Lisata regains full development rights to certepetide in the Greater China Region Lisata regains full development rights to certepetide in the Greater China Region
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an approximate 85% premium ove...
Lisata Therapeutics Earnings Call Transcript: Q3 2025
Q3 2025 saw reduced expenses and net loss, with $19M in cash projected to last into Q1 2027. Certepetide advanced across multiple cancer trials, showing positive efficacy and safety signals, while new partnerships and a key patent strengthened the pipeline.
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Data rich period continues to support certepetide's broad applicability and effectiveness Catalent enters into global license agreement for the use of certepetide as part of their SMARTag® Antibody-Dr...
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year'
BASKING RIDGE, N.J. , Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies fo...
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for...
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for...
Lisata Therapeutics Transcript: LD Micro Main Event XIX Investor Conference
A novel peptide adjuvant is showing significant survival and response improvements in solid tumor cancers, especially metastatic pancreatic cancer, with broad compatibility and no added toxicity. Multiple strategic partnerships, regulatory designations, and a strong financial position support ongoing and future clinical milestones.
Lisata Therapeutics to Present at LD Micro Main Event XIX
Basking Ridge, New Jersey--(Newsfile Corp. - October 13, 2025) - Lisata Therapeutics, Inc. (NASDAQ: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative th...
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
Catalent gains global rights to evaluate certepetide and its analogs for use as SMARTag® payloads across multiple ADCs designed to address difficult-to-treat diseases
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
Results to be presented at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions
Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
BASKING RIDGE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies fo...
Lisata Therapeutics Earnings Call Transcript: Q2 2025
Q2 2025 saw reduced expenses and a narrowed net loss, with $22M in cash supporting operations into Q4 2026. Multiple clinical milestones were achieved, including positive preliminary data for Certepetide and new strategic partnerships, while a key patent extended exclusivity to 2040.
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Cash runway extending into the fourth quarter of 2026 with no debt, funding current clinical programs through to their next data milestone
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
BASKING RIDGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for...
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
Compelling new preliminary data consistent with previously reported preclinical findings demonstrating certepetide's potential ability to enhance the effectiveness of immunotherapy Compelling new prel...
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extension
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development
Expanded alliance combines Lisata's drug development expertise with GATC's AI-powered Multiomics Advanced Technology® platform to accelerate and improve success rates of next-generation drug developme...
Lisata Therapeutics to Present at the 2025 BIO International Convention
BASKING RIDGE, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for...
Lisata Therapeutics Earnings Call Transcript: Q1 2025
Q1 2025 saw reduced expenses and net loss, with $25.8M in cash supporting operations into Q3 2026. Certepetide clinical programs advanced, with key trial data and milestones expected in the next 12–18 months. Multiple collaborations and licensing deals expand pipeline reach.
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025; Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025
Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025
BASKING RIDGE, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for ...
Lisata Therapeutics Announces Research License with Catalent
BASKING RIDGE, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies fo...
Lisata Therapeutics to Present at the Investival Showcase USA
BASKING RIDGE, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies fo...